Amneal 10-Q: Q3 Revenue Up 10% to $863M, but Kashiv Deal Drives $21.7M Quarterly Loss
AMRX sits 88% above its 52-week low of $11.295.
Summary
Amneal's Q3 10-Q confirms 10% revenue growth to $863 million but a $21.7 million net loss, driven by Kashiv acquisition costs and non-cash accretion rather than operations. The filing details a $1.3 billion Kashiv purchase price, $3.05 billion of debt and a cash balance down to $157 million.
Key Events · Earnings and Guidance · AMRX
-
Q3 Revenue Grows 10% to $863M
Net revenue rose to $862.7 million from $784.5 million, with gross profit up 22% to $334.1 million and operating income up 36% to $95.4 million.
-
Quarterly Net Loss of $21.7M
Net loss attributable to Amneal was $21.7 million (-$0.06/share), driven by $22.3 million of acquisition and integration costs and $14.2 million of redeemable NCI accretion; nine-month net income was $98.2 million.
-
Kashiv Deal Adds $1.3B to Balance Sheet
The August 10, 2026 acquisition carried $1.302 billion of consideration, including $1.003 billion of intangibles ($963 million IPR&D) and $179.5 million of goodwill, plus a $383 million contingent consideration liability.
-
Debt Rises, Cash Falls
Total debt reached $3.05 billion with $180 million drawn on the revolver, while cash and equivalents fell to $157.4 million from $282.0 million at December 31, 2025; nine-month operating cash flow was $50.3 million versus $209.7 million.
Analysis · AMRX · Life Sciences
The headline numbers have been out since November 3, so the revenue beat and guidance raise are already priced in. What's new is the full balance sheet and Kashiv purchase accounting: the $1.3 billion deal added $1.0 billion of intangibles and $383 million of contingent consideration, pushed total debt to $3.05 billion and cut cash to $157 million from $282 million at year-end. Nine-month operating cash flow fell to $50 million from $210 million on litigation and tax-receivable payments plus inventory build. The quarter's loss is largely non-cash and deal-related — $22.3 million of acquisition costs and $14.2 million of redeemable NCI accretion — not an operating deterioration, since operating income rose 36% to $95 million.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMRX was trading at $21.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.4B. The 52-week trading range was $11.29 to $21.68. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.